OrbiMed Advisors QTTB Position
ActiveOrbiMed Advisors held their position in Q32 Bio Inc. (QTTB) in Q4 2025, holding $7.5M worth of shares across 2,252,987 shares.
The position was first reported in Q1 2024 and has been tracked across 8 quarterly 13F filings.
1 other tracked fund also holds QTTB.
There is an upcoming Phase 2 readout for bempikibart (ADX-914) in 75 days (Jun 30, 2026), making the timing of OrbiMed's position particularly relevant.
About Q32 Bio Inc.
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
Full company profile →Short Interest
6.0%
1.6 days to cover
OrbiMed Advisors QTTB Position History
Frequently Asked Questions
Does OrbiMed Advisors own QTTB?
Yes. As of Q4 2025, OrbiMed Advisors holds 2,252,987 shares of Q32 Bio Inc. (QTTB) valued at $7.5M. This data comes from their SEC 13F filing.
How many hedge funds own QTTB?
2 specialist biotech hedge funds currently hold QTTB, including Eventide Asset Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy QTTB?
OrbiMed Advisors's position in QTTB was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's QTTB position increasing or decreasing?
OrbiMed Advisors held their QTTB position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
QTTBCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →